Please login to the form below

Not currently logged in
Email:
Password:

GSK benefiting from joint R&D

GlaxoSmithKline and Pozen announced on April 17 that the US Food and Drug Administration has approved the migraine medication Treximet
GlaxoSmithKline (GSK) and Pozen announced on April 17 that the US Food and Drug Administration (FDA) has approved the migraine medication Treximet.

Treximet has been developed to treat migraine and could be available in the US market as early as mid-May 2008. Trials into the drug have shown it to be more effective than sumatriptan and naproxen, two existing migraine medications, both of which are components of Treximet.

More than 3,700 migraine patients have been involved in extensive clinical trials that saw Treximet used to treat almost 30,000 migraine attacks.

Dr Stephen Silberstein, professor of neurology and director of the Jefferson Headache Centre at Thomas Jefferson University, said: "The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients."

"Migraine patients want their medicine to work early and to continue to provide relief," he added.

GSK has also announced an alliance with Regulus Therapeutics to launch an R&D programme to discover novel microRNA-targeted therapeutics for treating inflammatory conditions, such as rheumatoid arthritis and bowel disease. Regulus will be given a $20m upfront payment as part of the deal.

17th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics